Filing Flows › Castle Biosciences (CSTL) › R&D spending
Castle Biosciences (CSTL) R&D spending by quarter
Castle Biosciences' R&D spending was $15.8M in Q3 2026 (third quarter 2026), +9% from Q2 2026. Over the last 7 quarters it ranged from $12.6M (Q1 2025) to $15.8M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $15.8M | +9% | +22% |
| Q2 2026 | $14.5M | +0.8% | +14% |
| Q1 2026 | $14.4M | +7% | +15% |
| Q4 2025 | $13.5M | +4% | — |
| Q3 2025 | $13.0M | +1% | — |
| Q2 2025 | $12.8M | +2% | — |
| Q1 2025 | $12.6M | — | — |
Q3 2026 at a glance
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Castle Biosciences' R&D spending?
Castle Biosciences' R&D spending was $15.8M in Q3 2026 (third quarter 2026), +9% from Q2 2026.
How has Castle Biosciences' R&D spending changed?
Over the last 7 quarters it ranged from $12.6M (Q1 2025) to $15.8M (Q3 2026).